Prothena (PRTA) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Prothena in October 2026.
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Prothena (PRTA) Stock Forecast
Analyst price target, next 12 months
$43.22
+417.0% vs today's $8.36
Price range over the last 12 months
Close to its 12-month low
Analysts covering Prothena have a consensus 12-month target of $43.22, above the current price of $8.36.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 30 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Prothena's stock with a target price of $43.22, indicating possible growth.
Financial Health
Prothena is generating decent revenue and cash flow, but its overall financial health needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
